Last reviewed · How we verify
Micronized progesterone 200 MG
Micronized progesterone 200 MG, marketed by Andros Day Surgery Clinic, is a currently available pharmaceutical product with a key composition patent expiring in 2028. The drug's market position is bolstered by its patent protection, which provides a competitive advantage until expiry. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market.
At a glance
| Generic name | Micronized progesterone 200 MG |
|---|---|
| Also known as | Prometrium, Sequential |
| Sponsor | Andros Day Surgery Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
- Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix (NA)
- No More Sleepless Nights in Perimenopause (PHASE4)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronized progesterone 200 MG CI brief — competitive landscape report
- Micronized progesterone 200 MG updates RSS · CI watch RSS
- Andros Day Surgery Clinic portfolio CI